Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3678573 | 0.89 | MAPT (0.72) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL6047059 | 0.85 | MAPT (0.67) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| Tretazicar SCHEMBL29375352 | 0.84 | MAPT (1.00) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| Tretazicar SCHEMBL366755 | 0.84 | MAPT (1.00) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL13685668 | 0.81 | MAPT (0.78) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL5581335 | 0.81 | MAPT (0.78) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL3503280 | 0.81 | MAPT (0.55) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL13685644 | 0.80 | MAPT (0.58) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL29391567 | 0.78 | MAPT (0.72) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL3362694 | 0.78 | MAPT (0.72) | MAPTCYP3A4BLMPMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119674357-A | Battery cell shell and battery cell | 蜂巢能源科技股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4186112-A1 | SUPERCONDUCTING STRUCTURE AND DEVICE SURFACE TERMINATION WITH ALLOY | International Business Machines Corporation (US) | 2023-05-31 | — | — | EP | claimed |
| CN-107080746-B | Using alpha-hydroxycarbonyl compounds as reducing agents | 高典制药有限公司 | 2021-08-06 | — | — | CN | claimed |
| US-10398676-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | MORVUS TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | claimed |
| US-20180140575-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2018-05-24 | — | — | US | claimed |
| US-9907784-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | MORVUS TECHNOLOGY LIMITED (GB) | 2018-03-06 | — | — | US | claimed |
| EP-2258430-B1 | 5-(Aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide and its use in medicine | MORVUS TECH LTD (GB) | 2017-03-22 | — | — | EP | claimed |
| US-20150231113-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2015-08-20 | — | — | US | claimed |
| US-9029569-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | MORVUS TECHNOLOGY LIMITED (GB) | 2015-05-12 | — | — | US | claimed |
| CN-103315995-A | Use of alpha-hydroxy carbonyl compounds as reducing agents | MORVUS TECHNOLOGY LTD | 2013-09-25 | — | — | CN | claimed |
| EP-1951213-B1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | MORVUS TECHNOLOGY LTD (GB) | 2012-11-14 | — | — | EP | claimed |
| EP-2258430-A2 | 5-(Aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide and its use in medicine | Morvus Technology Ltd. (GB) | 2010-12-08 | — | — | EP | claimed |
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2010-04-29 | — | — | US | claimed |
| WO-2009111177-A2 | COMPOSITIONS AND METHODS COMPRISING GENETICALLY ENHANCED OBLIGATE AND FACULTATIVE ANAEROBIC BACTERIA FOR ONCOPATHIC CANCER THERAPY | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2009-09-11 | — | — | WO | claimed |
| CN-101389320-A | Using alpha-hydroxycarbonyl compounds as reducing agents | MORVUS TECHNOLOGY LTD (GB) | 2009-03-18 | — | — | CN | claimed |
| EP-1951213-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | Morvus Technology Ltd. (GB) | 2008-08-06 | — | — | EP | claimed |
| WO-2007074344-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | MORVUS TECHNOLOGY LIMITED (GB) | 2007-07-05 | — | — | WO | claimed |
| EP-0429454-A1 | IMPROVEMENTS RELATING TO THE CONTROL OF NEOPLASTIC TISSUE GROWTH | Roberts, John J. (GB) | 1991-06-05 | — | — | EP | claimed |
| EP-0330432-A1 | Improvements relating to the control of neoplastic tissue growth | Roberts, John J. (GB) | 1989-08-30 | — | — | EP | claimed |
| WO-1989007592-A1 | IMPROVEMENTS RELATING TO THE CONTROL OF NEOPLASTIC TISSUE GROWTH | ROBERTS JOHN J (GB) | 1989-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | MAPT 3157/4885CYP3A4 456/4885BLM 3799/4885 |
| US-10398676-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | DERA, HOGA1, ALDOA | MAPT 3157/4885CYP3A4 456/4885BLM 3799/4885 |
| US-20180140575-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | MAPT 3157/4885CYP3A4 456/4885BLM 3799/4885 |
| US-20150231113-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | MAPT 3157/4885CYP3A4 456/4885BLM 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.